1 Wang Y, Han B, Fan Y, et al. Next-generation sequencing reveals novel genetic variants for dilated cardiomyopathy in pediatric Chinese patients[J]. Pediatr Cardiol, 2022, 43(1): 110-120. PMID: 34350506. DOI: 10.1007/s00246-021-02698-8.
2 郑奎, 张英谦, 刘露, 等. 32例儿童心肌病基因检测与临床特征分析[J]. 临床心血管病杂志, 2022, 38(7): 566-571. DOI: 10.13201/j.issn.1001-1439.2022.07.010.
3 Azad A, Poloni G, Sontayananon N, et al. The giant titin: how to evaluate its role in cardiomyopathies[J]. J Muscle Res Cell Motil, 2019, 40(2): 159-167. PMID: 31147888. PMCID: PMC6726704. DOI: 10.1007/s10974-019-09518-w.
4 Tharp CA, Haywood ME, Sbaizero O, et al. The giant protein titin's role in cardiomyopathy: genetic, transcriptional, and post-translational modifications of TTN and their contribution to cardiac disease[J]. Front Physiol, 2019, 10: 1436. PMID: 31849696. PMCID: PMC6892752. DOI: 10.3389/fphys.2019.01436.
5 Liu G, Yang Z, Chen W, et al. Novel missense variant in TTN cosegregating with familial atrioventricular block[J]. Eur J Med Genet, 2020, 63(3): 103752. PMID: 31470098. DOI: 10.1016/j.ejmg.2019.103752.
6 王晶, 徐文峰, 陈頔, 等. 治疗45外显子跳跃突变杜氏肌营养不良症的药物——Casimersen[J]. 临床药物治疗杂志, 2022, 20(5): 17-20. DOI: 10.3969/j.issn.1672-3384.2022.05.004.
7 Loescher CM, Hobbach AJ, Linke WA. Titin (TTN): from molecule to modifications, mechanics, and medical significance[J]. Cardiovasc Res, 2022, 118(14): 2903-2918. PMID: 34662387. PMCID: PMC9648829. DOI: 10.1093/cvr/cvab328.
8 Gerull B. The rapidly evolving role of titin in cardiac physiology and cardiomyopathy[J]. Can J Cardiol, 2015, 31(11): 1351-1359. PMID: 26518445. DOI: 10.1016/j.cjca.2015.08.016.
9 Santiago CF, Huttner IG, Fatkin D. Mechanisms of TTN tv-related dilated cardiomyopathy: insights from zebrafish models[J]. J Cardiovasc Dev Dis, 2021, 8(2): 10. PMID: 33504111. PMCID: PMC7912658. DOI: 10.3390/jcdd8020010.
10 Kellermayer D, Smith JE, Granzier H. Titin mutations and muscle disease[J]. Pflugers Arch, 2019, 471(5): 673-682. PMID: 30919088. PMCID: PMC6481931. DOI: 10.1007/s00424-019-02272-5.
11 Tharp C, Mestroni L, Taylor M. Modifications of titin contribute to the progression of cardiomyopathy and represent a therapeutic target for treatment of heart failure[J]. J Clin Med, 2020, 9(9): 2770. PMID: 32859027. PMCID: PMC7564493. DOI: 10.3390/jcm9092770.
12 Dai G, Pu Z, Cheng X, et al. Whole-exome sequencing reveals novel genetic variation for dilated cardiomyopathy in pediatric Chinese patients[J]. Pediatr Cardiol, 2019, 40(5): 950-957. PMID: 30993396.DOI: 10.1007/s00246-019-02096-1.
13 Khan RS, Pahl E, Dellefave-Castillo L, et al. Genotype and cardiac outcomes in pediatric dilated cardiomyopathy[J]. J Am Heart Assoc, 2022, 11(1): e022854. PMID: 34935411.PMCID: PMC9075202.DOI: 10.1161/JAHA.121.022854.
14 Akinrinade O, Heli? T, Lekanne Deprez RH, et al. Relevance of titin missense and non-frameshifting insertions/deletions variants in dilated cardiomyopathy[J]. Sci Rep, 2019, 9(1): 4093. PMID: 30858397. PMCID: PMC6412046. DOI: 10.1038/s41598-019-39911-x.
15 李发有, 范洁. 肌联蛋白基因截断突变致家族性扩张型心肌病的研究进展[J]. 中国循环杂志, 2015, 30(7): 715-717. DOI: 10.3969/j.issn.1000-3614.2015.07.025.
16 Fatkin D, Huttner IG. Titin-truncating mutations in dilated cardiomyopathy: the long and short of it[J]. Curr Opin Cardiol, 2017, 32(3): 232-238. PMID: 28151760. DOI: 10.1097/HCO.0000000000000382.
17 Vikhorev PG, Vikhoreva NN, Yeung W, et al. Titin-truncating mutations associated with dilated cardiomyopathy alter length-dependent activation and its modulation via phosphorylation[J]. Cardiovasc Res, 2022, 118(1): 241-253. PMID: 33135063. PMCID: PMC8752363. DOI: 10.1093/cvr/cvaa316.
18 Fomin A, G?rtner A, Cyganek L, et al. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations[J]. Sci Transl Med, 2021, 13(618): eabd3079. PMID: 34731013. DOI: 10.1126/scitranslmed.abd3079.
19 Biquand A, Spinozzi S, Tonino P, et al. Titin M-line insertion sequence 7 is required for proper cardiac function in mice[J]. J Cell Sci, 2021, 134(18): jcs258684. PMID: 34401916. PMCID: PMC8466004. DOI: 10.1242/jcs.258684.
20 Zhu C, Yin Z, Ren J, et al. RBM20 is an essential factor for thyroid hormone-regulated titin isoform transition[J]. J Mol Cell Biol, 2015, 7(1): 88-90. PMID: 25573899. PMCID: PMC4400401. DOI: 10.1093/jmcb/mjv002.
21 Hidalgo C, Hudson B, Bogomolovas J, et al. PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness[J]. Circ Res, 2009, 105(7): 631-638, 17 p following 638. PMID: 19679839. PMCID: PMC2764991. DOI: 10.1161/CIRCRESAHA.109.198465.
22 Schafer S, de Marvao A, Adami E, et al. Titin-truncating variants affect heart function in disease cohorts and the general population[J]. Nat Genet, 2017, 49(1): 46-53. PMID: 27869827. PMCID: PMC5201198. DOI: 10.1038/ng.3719.
23 Adams M, Fleming JR, Riehle E, et al. Scalable, non-denaturing purification of phosphoproteins using Ga3+-IMAC: N2A and M1M2 titin components as study case[J]. Protein J, 2019, 38(2): 181-189. PMID: 30719619. DOI: 10.1007/s10930-019-09815-w.
24 Verdonschot JAJ, Hazebroek MR, Derks KWJ, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias[J]. Eur Heart J, 2018, 39(10): 864-873. PMID: 29377983. DOI: 10.1093/eurheartj/ehx808.
25 Linschoten M, Teske AJ, Baas AF, et al. Truncating titin (TTN) variants in chemotherapy-induced cardiomyopathy[J]. J Card Fail, 2017, 23(6): 476-479. PMID: 28315399. DOI: 10.1016/j.cardfail.2017.03.003.
26 Ware JS, Cook SA. Role of titin in cardiomyopathy: from DNA variants to patient stratification[J]. Nat Rev Cardiol, 2018, 15(4): 241-252. PMID: 29238064. DOI: 10.1038/nrcardio.2017.190.
27 Franaszczyk M, Chmielewski P, Truszkowska G, et al. Titin truncating variants in dilated cardiomyopathy: prevalence and genotype-phenotype correlations[J]. PLoS One, 2017, 12(1): e0169007. PMID: 28045975. PMCID: PMC5207678. DOI: 10.1371/journal.pone.0169007.
28 Ahlberg G, Refsgaard L, Lundegaard PR, et al. Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation[J]. Nat Commun, 2018, 9(1): 4316. PMID: 30333491. PMCID: PMC6193003. DOI: 10.1038/s41467-018-06618-y.
29 Enriquez A, Liang J, Smietana J, et al. Substrate characterization and outcomes of ventricular tachycardia ablation in TTN (titin) cardiomyopathy: a multicenter study[J]. Circ Arrhythm Electrophysiol, 2021, 14(9): e010006. PMID: 34315225. DOI: 10.1161/CIRCEP.121.010006.
30 Pe?a-Pe?a ML, Ochoa JP, Barriales-Villa R, et al. Prognostic implications of pathogenic truncating variants in the TTN gene[J]. Int J Cardiol, 2020, 316: 180-183. PMID: 32371228. DOI: 10.1016/j.ijcard.2020.04.086.
31 Gramlich M, Pane LS, Zhou Q, et al. Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy[J]. EMBO Mol Med, 2015, 7(5): 562-576. PMID: 25759365. PMCID: PMC4492817. DOI: 10.15252/emmm.201505047.
32 Hahn JK, Neupane B, Pradhan K, et al. The assembly and evaluation of antisense oligonucleotides applied in exon skipping for titin-based mutations in dilated cardiomyopathy[J]. J Mol Cell Cardiol, 2019, 131: 12-19. PMID: 30998980. DOI: 10.1016/j.yjmcc.2019.04.014.